An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials Robert M. ZuckerDavid J. AdamsKenneth H. Elstein Preclinical Studies Pages: 1 - 15
Activity of a recombinant transforming growth factor-α-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units Daniel D. Von HoffMartha H. MarshallAllen Oliff Preclinical Studies Pages: 17 - 22
Phase II trial of didemnin-B in advanced epithelial ovarian cancer Joanna M. CainP. Y. LiuJohn N. Bickers Clinical Studies Pages: 23 - 24
Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix Hyman B. MussJohn A. BlessingRamon McGehee Clinical Studies Pages: 25 - 26
Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma Thomas LadJoel SchorLinda Weidner Brief Report Pages: 27 - 28
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung Stephen K. WilliamsonJohn J. CrowleyJames H. Doroshow Brief Report Pages: 29 - 30
Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy Michael D. GreenPeter ShermanJohn Zalcberg Brief Report Pages: 31 - 34
Menogaril in the treatment of relapsed multiple myeloma Julia M. CruzL. Douglas CaseR. L. Capizzi Brief Report Pages: 35 - 37
Phase II trial of fazarabine in advanced colorectal carcinoma Kevin P. HubbardKaren DaughertyJames L. Abbruzzese Brief Report Pages: 39 - 42
Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer Ronald S. WaltersRichard L. TheriaultLaura Esparza Brief Report Pages: 43 - 44
Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose Melphalan with autologous bone marrow transplantation William J. SlichenmyerC. F. LeMaistreDaniel D. Von Hoff Brief Report Pages: 45 - 48
Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma Robert S. WitteChristine WalshDonald L. Trump Brief Report Pages: 49 - 50
Trimetrexate in advanced renal cell carcinoma Robert S. WittePaul ElsonDonald L. Trump Brief Report Pages: 51 - 54
Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney Sarah A. TaylorPhyllis GoodmanEllen R. Gaynor Brief Report Pages: 55 - 56